Eden Research plc - Grant of 'Emergency use' authorisation
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the
("Eden" or "Company")
France grants 120-day "emergency" authorisation for use on apples
Mevalone offer growers tremendous advantages by providing efficacy against important crop diseases with active ingredients that are exempt from residue limits and the ability to apply the product just prior to harvest. The benefits of Mevalone are further expanded in this new use as growers are now able to extend the shelf-life of apples and help to reduce food waste and cost in the supply chain. Regulatory authorisation of Mevalone for this use in
"Whist this derogation is valid until the 21st of
For further information contact:
| || |
01285 359 555
Cenkos Securities (Nominated advisor and broker)
| || |
020 7397 8900
Powerscourt (Financial PR)
020 7250 1446
Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £13m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.
Mevalone has been authorised for sale in
Eden was admitted to trading on AIM on
For more information about Eden, please visit: www.edenresearch.com.
This information is provided by RNS, the news service of the
Quick facts: Eden Research PLC
Market Cap: £25.48 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE